A previous RCT compared the efficacy of immunotherapy versus treatment of physician’s choice in third-line therapy for advanced esophageal cancer. The results showed that the OS was 4.6 months and 5.0 months in the two groups, respectively.
免疫疗法与医生选择治疗在晚期食管癌三线治疗中的疗效对比
本文基于随机对照试验(RCT)研究，对比免疫疗法与医生选择治疗在晚期食管癌三线治疗中的疗效。结果显示，两组的总生存期(OS)分别为4.6个月和5.0个月，提供详细数据分析与临床意义解读。
与梅斯小智对话
